Labeled Galectin Detection Agents for Imaging Precision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and assessing galectins, which are proteins involved in various diseases such as cancer and inflammatory processes, lack effective compositions and techniques for imaging and detection.
Innovation Solution
Development of labeled compositions that include radioactive or fluorescent labels, allowing for nuclear and fluorescent imaging of galectins by forming complexes with them, enabling detection and assessment of galectin levels in subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for galectins, then the detection process is simple, but the measurement precision and imaging capability are insufficient
Solution Approach 1:
The patent introduces labeled compositions (radioactive or fluorescent labels) as intermediaries that bind to galectins. These labels serve as mediators between the galectin target and the detection system, enabling precise imaging through PET, SPECT, or fluorescence techniques while maintaining relatively simple procedural steps.
Solution Approach 2:
The patent employs different types of labels (radioactive isotopes like 18F, 123I, 124I, 125I, 131I, or fluorescent labels) to change the detection parameters. By selecting appropriate labels based on the desired imaging modality, the system achieves high measurement precision for galectin detection and assessment.
2Difficulty of detecting and measuring
If no imaging compositions are used, then the detection method is straightforward, but the ability to image and assess galectin levels is lacking
Solution Approach 1:
Labeled compositions act as intermediaries that provide the necessary imaging capability. The radioactive or fluorescent labels enable detection and imaging of galectins without requiring large quantities of the target protein, as the labels amplify the signal for detection.
Solution Approach 2:
The patent utilizes fluorescent labels that emit light at specific wavelengths when excited, and radioactive labels that emit detectable radiation. These optical and radiological property changes enable imaging and quantification of galectin levels with high sensitivity, overcoming the limitation of insufficient imaging capability.
3Measurement precision
If labeled compositions are developed for galectin detection, then imaging precision is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent describes systematic methods for synthesizing labeled compositions by first preparing the appropriate chemical structures (compounds of formulas I-IX) and then incorporating the radioactive or fluorescent labels. This preliminary preparation of the molecular framework facilitates the subsequent labeling step, making the manufacturing process more manageable despite the complexity introduced by the labels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise imaging and detection of galectins, aiding in the diagnosis and potential treatment of conditions characterized by galectin upregulation, including cancer and inflammatory processes, through PET, SPECT, or fluorescence imaging.
Implementation Method 1
Galectins are a group of proteins known for their ability to bind to β-galactoside sugars, either by N-linked or O-linked glycosylation
Implementation Method 2
where R6 is a radioactive or fluorescent label
Implementation Method 3
where R6 is a radioactive or fluorescent label
Data Source
AI summary
Compositions and methods for detection and assessment of galectins are provided by the present invention, including labeled compositions, pharmaceutical composition including a labeled composition for galectin detection and a pharmaceutically acceptable carrier, method of aiding in diagnosis and/or treatment of a condition characterized by upregulation of one or more galectins in a subject in need thereof and precursor compositions for synthesis of chemical compositions, including but not limited to labeled compositions for detection and assessment of galectins.